Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.69 |
| ▸ | WNT3A | P56704 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | TPMT | P51580 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10455919 | 0.89 | CTNNB1 (0.83) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL24375732 | 0.87 | SLC22A6 (0.62) | CTNNB1WNT3ACYP1A2GAAMEN1 | |
| SCHEMBL31556192 | 0.86 | CTNNB1 (0.73) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL27261724 | 0.85 | CTNNB1 (0.63) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL6600362 | 0.84 | CTNNB1 (0.71) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL31556194 | 0.84 | CTNNB1 (0.71) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL30092278 | 0.84 | CTNNB1 (0.71) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL30313764 | 0.84 | CTNNB1 (0.71) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL29060617 | 0.84 | CTNNB1 (0.71) | CTNNB1WNT3AMAPTTSHRCYP1A2 | |
| SCHEMBL14483927 | 0.83 | CTNNB1 (0.69) | CTNNB1WNT3AMAPTTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | LAWRENCE NICHOLAS JAMES (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1444190-A1 | COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY | Cancer Research Technology Limited (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040077-A1 | COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-05-15 | — | — | WO | disclosed |
| EP-0680950-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0680950-A1 | PROPENONE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | AURKA, AURKB, HDAC4 | CTNNB1 4243/4885WNT3A 2982/4885MAPT 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.